ORMP
Oramed Pharmaceuticals Inc.3.0800
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
122.73MP/E (TTM)
3.08Basic EPS (TTM)
1.00Dividend Yield
0%Recent Filings
8-K
Oramed finalizes $28.5M warrant sale
Oramed Pharmaceuticals completed the final tranche of its warrant repurchase with Scilex on December 30, 2025, selling warrants for 3,370,000 shares of Scilex common stock for $14M, including prepayments. This wraps the two-tranche deal, netting Oramed $28.5M total from Scilex. Cash locked in. No further terms disclosed.
8-K
Director Sank resigns
8-K
Oramed nets $65M on investments
Oramed reported $65.0 million pre-tax net income for the nine months ended September 30, 2025, versus a $6.1 million loss last year, fueled by full $100 million Scilex repayment and unrealized gains from Alpha Tau holdings. Total assets surged 42% to $220.5 million. Investment strategy pays off. Yet market volatility risks loom over the portfolio.
8-K
Adopts shareholder rights plan
Oramed Pharmaceuticals declared a dividend of one common stock purchase right per share, payable November 27, 2025, to protect against hostile takeovers. Rights trigger if any party hits 15% ownership, letting others buy shares worth twice the $10 exercise price—while the acquirer's rights void. Board can redeem at $0.012 anytime before. Pill expires in three years.
10-Q
Q3 FY2025 results
Oramed swung to a $54.0M net profit for the nine months ended September 30, 2025, up from a $8.9M loss y/y, driven by $74.3M financial income (derived) from Alpha Tau and Scilex revaluations that dwarfed a $9.4M operating loss. Q3 alone delivered $48.4M profit versus a $19.6M loss y/y, with diluted EPS of $1.13 on 42.8M shares. Cash sits at $52.2M, bolstered by $136.1M current assets against $6.1M liabilities; stock repurchases totaled $0.7M. Alpha Tau stake hit $64.8M after April 2025's $36.9M buy. Yet Alpha Tau's clinical risks loom large.
ARMP
Armata Pharmaceuticals, Inc.
5.72-0.44
OCEA
Ocean Biomediacal, Inc.
0.00+0.00
OGEN
Oragenics Inc.
0.83-0.01
OMER
Omeros Corporation
8.77-0.43
ORGS
Orgenesis, Inc.
0.15-0.01
ORIC
Oric Pharmaceuticals, Inc.
9.12-0.11
ORKA
Oruka Therapeutics, Inc.
28.94-1.16
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
OVID
Ovid Therapeutics Inc.
1.55-0.01
TELO
Telomir Pharmaceuticals, Inc.
1.40-0.02